PRINCETON, N.J. — The ophthalmic and otic products of Falcon Pharmaceuticals Ltd., the U.S. generics business of Alcon Inc., are being brought under the Sandoz umbrella.

Sandoz, the generic pharmaceuticals arm of Novartis, said Tuesday that the Falcon products are slated to become part of its U.S. portfolio this month.

The move stems from Novartis’ acquisition of Alcon, which was completed in April, Sandoz said. According to the company, the addition of the Falcon products makes Sandoz the largest manufacturer and marketer of generic ophthalmic and otic products in the United States.

Sandoz added that the transfer of Falcon products also expands its portfolio of differentiated, complex generic medicines and bolster the company’s technical expertise and experience in the ophthalmic and otic treatment areas.

"We are pleased to announce the addition of the Falcon product line to our U.S. portfolio as an important step in maximizing the value of the Novartis acquisition of Alcon," Don DeGolyer, president of Sandoz, said in a statement. "This product transfer allows us to expand our robust offering of cost-saving generic treatments to patients and customers in the U.S., reinforcing Sandoz’s leadership in providing high-quality, affordable medicines across key differentiated categories."

With the addition of the Falcon products, Sandoz now offers more than 30 families of single and multisource generic ophthalmic and otic products, and the company said it plans to add a number of new products in the near term.